Publications
- Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer2018 | First Faculty of Medicine, Second Faculty of Medicine
- Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure inhibit prostate tumor growth in TRAMP mice2017 | Second Faculty of Medicine
- Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy2016 | Second Faculty of Medicine
- Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer2015 | Second Faculty of Medicine
- Trial Watch Dendritic cell-based interventions for cancer therapy2013 | Second Faculty of Medicine
- Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response2011 | First Faculty of Medicine, Faculty of Physical Education and Sport, Second Faculty of Medicine
- FOCUS on FOCIS: Combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer2009 | First Faculty of Medicine, Faculty of Physical Education and Sport, Second Faculty of Medicine
- Imunogenic cell death and it ´s application in immunotherapy protocolsPublication without faculty affiliation
- Type I interferon and cancer2024 | Second Faculty of Medicine
- Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients2023 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Pilsen
Loading network view...